Video
Dr. Meeks recaps LUGPA panel on optimizing advanced bladder cancer clinic
Author(s):
"There's 3000 patient trials that are either done or going to be done within the next year or 2 in the BCG-naïve setting, and all of them have systemic therapy," says Joshua J. Meeks, MD, PhD.
Joshua J. Meeks, MD, PhD, is an associate professor of urology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. In this interview, Meeks recaps a panel discussion on ABCC optimization, which took place at the 2022 LUGPA Annual Meeting in Chicago.
Related Videos
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Amy Krambeck, MD, on innovation and building strong programs in endourology
Expert discusses the NMIBC trials landscape
5 key trial insights from AUA 2025
Endourologist discusses shared decision-making and laser lithotripsy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Related Content
